HESTER BIOSCIENCES LTD.
P&L
Quarterly Consolidated
vs Q2 FY25
Hester Biosciences Q3 & 9M FY25 Results: Standalone Performance Divisional Sales Up, Profit Up for 9M FY25, Down for Q3 FY25; Consolidated Performance Divisional Sales Up, Profit Up for 9M & Q3 FY25
30 Jan 2025 · 30 Jan 2025, 05:52 pm
Summary
Hester Biosciences Limited announced its unaudited financial results for Q3 & 9M FY25. The standalone performance showed a 14% growth in divisional sales for 9M FY25, but a 4% decline in Q3 FY25. The profit, however, increased by 13% for 9M FY25 but decreased by 31% in Q3 FY25. The consolidated performance saw a 2% growth in divisional sales for 9M FY25 and a 6% decline in Q3 FY25, with profits up by 85% for 9M FY25 and 184% in Q3 FY25. The company's Poultry Healthcare Division and Petcare Division achieved impressive growth, while the Animal Healthcare Division faced some challenges.
Key Highlights
- 1
Standalone divisional sales up by 14% for 9M FY25, but down by 4% in Q3 FY25
- 2
Profit up by 13% for 9M FY25, but down by 31% in Q3 FY25
- 3
Consolidated divisional sales up by 2% for 9M FY25, but down by 6% in Q3 FY25
- 4
Profit up by 85% for 9M FY25, and 184% in Q3 FY25
- 5
Poultry Healthcare Division and Petcare Division achieved impressive growth
- 6
Animal Healthcare Division faced some challenges
Management Comments
Vinod Senici Mali
The immunisation programs are progressing as scheduled, with the company prioritising the Government of India’s initiatives through the consistent supply of Goat Pox and PPR vaccines. We are confident of turning around this degrowth in the coming quarters.
Informational and educational content only. Not investment advice.